1197880-08-2

Upstream product

• 1197880-09-3 (E)-methyl 3-(4-((2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl)phenyl)acrylate 
• 154553-72-7 2-ethyl-5,7-dimethyl-3-(4-bromobenzyl)imidazo<4,5-b>pyridine 
• 133240-06-9 5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine 
• 123-54-6 acetylacetone 
• 7144-20-9 2-Amino-4,6-dimethylnicotinamide 

Downstream Products

• 1197880-12-8 3-[4-(2-Ethyl-5,7-dimethyl-imidazo[4,5-b]pyridin-3-ylmethyl)-phenyl]-propan-1-ol 
• 1197879-16-5 (E)-2-ethyl-3-(4-(3-(4-isopropylpiperazin-1-yl)prop-1-en-1-yl)benzyl)-5,7-dimethyl-3H-imidazo[4,5-b]pyridine 

Relevant academic research and scientific papers

Design and synthesis of potent and orally active GPR4 antagonists with modulatory effects on nociception, inflammation, and angiogenesis

GPR4, a G-protein coupled receptor, functions as a proton sensor being activated by extracellular acidic pH and has been implicated in playing a key role in acidosis associated with a variety of inflammatory conditions. An orally active GPR4 antagonist 39c was developed, starting from a high throughput screening hit 1. The compound shows potent cellular activity and is efficacious in animal models of angiogenesis, inflammation and pain.

IMIDAZO PYRIDINE DERIVATIVES

The invention relates to novel imidazopyridine derivatives and to their use in the treatment of diseases and disorders which may e.g. involve angiogenesis and/or pain, including autoimmune and inflammatory diseases.